Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by lscfaon Apr 14, 2021 6:53pm
120 Views
Post# 32997729

RE:RE:RE:RE:RE:RE:RE:RE:Labs will become king

RE:RE:RE:RE:RE:RE:RE:RE:Labs will become king

Will Valens results give any hint?
 

 

Qtr ending

Revenue

ebitda

ebitda margin

gross margin

Feb 21

21,774

(2,241)

(10.3%)

21.9%

Nov 20

16,044

(4,280)

(26.7%)

24.2% Adj

Aug 20

18,128

1,440

7.9%

39.5%

May 20

17,627

2,699

15.3%

35.8%

Feb 20

31,980

14,282

44.7%

56.6%

Nov 19

30,624

17,669

57.7%

73.8%

Aug 19

16,462

9,772

59.4%

77.8%

May 19

8,800

2,023

23.0%

57.9%

Feb 19

2,220

(2,028)

(91.4%)

38.3%

 



Lemoyne wrote: What I am saying is everyone is in the dark, even management to some extent, as to how future will play out. I didn't say it won't/can't improve, I said there are no numbers/analysis allowing you to predict future improvement. They've been shelling out news releases for a year without top-line improvement.

Basically, this is a speculative buy at this point. Very high risk. It could take off to the moon or drop dead and everything that's in between.

 

<< Previous
Bullboard Posts
Next >>